In Vivo Measurement of the Accuracy of the "Neurolocate" Module of the Neurosurgical Robot "Neuromate" in Its Application to Deep Brain Stimulation
In Vivo Measurement of the Accuracy of the "Neurolocate" Module of the Neurosurgical Robot "Neuromate" in Its Application to Deep Brain Stimulation
The purpose of this study is to evaluate the accuracy of the Neurolocate recording system of
 the neurosurgical robot Neuromate, marketed by Renishaw, in order to optimize surgical
 procedures, costs and patient comfort.
Robotic neurosurgery has been developed for nearly 25 years and offers neurosurgeons many
 advantages, including increased precision.

 Accuracy is a key point for stereotactic neurosurgical procedures, particularly for deep
 brain stimulation electrode implantations.

 The accuracy of the Neuromate robot was measured in stereotactic framed and frameless mode in
 vitro and in vivo during stereo-electroencephalography procedures. Investigators also
 evaluated the actual accuracy of its application in routine deep brain stimulation procedures
 using a measurement system independent of the robot itself and the manufacturer. We showed
 that the average in vivo accuracy was 0.86 mm and the maximum error was 1.55 mm. This
 accuracy is at least similar to the accuracy of stereotactic frame arms and is compatible
 with the accuracy required in deep brain stimulation procedures.

 The Neurolocate device is a new non-invasive, frameless patient matching module designed for
 use with the Neuromate stereotactic robot.

 The main advantages of the Neurolocate system are that it is less invasive than screw-on
 markers, simplifies the surgical procedure and reduces the duration of the surgery The
 accuracy of the Neurolocate frameless recording system was evaluated in vitro and in vivo for
 robotic stereo-electroencephalography trajectories in epileptic patients and compared to the
 accuracy of conventional recording using a stereotactic frame.

 However, the accuracy of the Neurolocate recording system has never been measured in vivo
 during deep brain stimulation procedures.
Inclusion Criteria:

 -  Patients aged 18 to 70 years old requiring a stereotactic robot-guided deep brain
 stimulation procedure

 -  Signature of the Informed Consent Form

 -  Affiliation to the French social security system

 Exclusion Criteria:

 -  Contraindication to MRI

 -  Hypersensitivity to gadoteric acid, meglumine or any product containing gadolinium.

 -  Anterior and posterior commissure anatomy modifying brain anatomy

 -  Patient unable to complete the Comfort Questionnaire due to cognitive or speech
 impairment

 -  Pregnant or breastfeeding women